GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » FCF Yield %

CVKD (Cadrenal Therapeutics) FCF Yield % : -21.20 (As of Mar. 30, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Cadrenal Therapeutics's Trailing 12-Month Free Cash Flow is $-7.36 Mil, and Market Cap is $34.70 Mil. Therefore, Cadrenal Therapeutics's FCF Yield % for today is -21.20%.

The historical rank and industry rank for Cadrenal Therapeutics's FCF Yield % or its related term are showing as below:

CVKD' s FCF Yield % Range Over the Past 10 Years
Min: -21.2   Med: 0   Max: 0
Current: -21.2


CVKD's FCF Yield % is ranked worse than
57.99% of 1502 companies
in the Biotechnology industry
Industry Median: -14.915 vs CVKD: -21.20

Cadrenal Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.


Cadrenal Therapeutics FCF Yield % Historical Data

The historical data trend for Cadrenal Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics FCF Yield % Chart

Cadrenal Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
FCF Yield %
- -36.67 -28.52

Cadrenal Therapeutics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.82 -75.22 -81.30 -52.23 -27.74

Competitive Comparison of Cadrenal Therapeutics's FCF Yield %

For the Biotechnology subindustry, Cadrenal Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cadrenal Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadrenal Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Cadrenal Therapeutics's FCF Yield % falls into.


;
;

Cadrenal Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Cadrenal Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-7.365 / 25.82118
=-28.52%

Cadrenal Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-1.791 * 4 / 25.82118
=-27.74%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cadrenal Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Cadrenal Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadrenal Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
Executives
John Raymond Murphy director 233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham director, 10 percent owner, officer: CEO and Chairman 89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo officer: Chief Medical Officer 13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske director 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot officer: Chief Financial Officer 802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson director 2483 NE JULEP STREET, ISSAQUAH WA 98029